Potentiation of VP-16 Cytotoxicity by Dipyridamole in Malignant Glioma Cells

  • Takanori Ohnishi
  • Hiromitsu Iwasaki
  • Norio Arita
  • Shoju Hiraga
  • Toru Hayakawa


VP-16 (etoposide) has been currently used for the treatment of malignant gliomas not only as a chemotherapeutic agent for induction of initial remission but also as a drug for the long-term treatment after remission of the tumors. When VP-16 is used for the latter purpose, however, two major problems should be solved in order to obtain a successful result with this drug. One is to overcome VP-16-resistant cells which may appear in the course of the treatment, and the other is to develop a new mode to treat G0/G1 cells which predominate after intensive treatment of the tumors. These cells make VP-16 cytotoxicity less effective due to the lower amount of DNA topoisomerase II, a target of VP-16 [1].


Glioma Cell Malignant Glioma Glioma Cell Line U373MG Cell T98G Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Long BH, Musial ST, Brattain MG (1985) Single and double strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 45: 3106–3112PubMedGoogle Scholar
  2. 2.
    Paterson ARP, Lau EY, Dahlig E, Cass CE (1980) A common basis for inhibition of nucleoside transport by dipyridamole and nitrobenzylthioinosine. Mol Pharmacol 18: 40–44PubMedGoogle Scholar
  3. 3.
    Aronow B, Ullman B (1986) Role of the nucleoside transport function in the transport and salvage of purine nucleobases. J Biol Chem 261: 2014–2019PubMedGoogle Scholar
  4. 4.
    Nelson JA, Drake S (1984) Potentiation of methotrexate toxicity by dipyridamole. Cancer Res 44: 2493–2496PubMedGoogle Scholar
  5. 5.
    Grem JL, Fischer PH (1985) Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res 45: 2967–2972PubMedGoogle Scholar
  6. 6.
    Ikegami T, Kubota N, Matsui K, Funabiki T, Shuin T (1989) Enhance effect of etoposide by dipyridamole (abstract). Proc Jpn Cancer Assoc 48: 30Google Scholar
  7. 7.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63PubMedCrossRefGoogle Scholar
  8. 8.
    Gros P, Croop J, Housman D (1986) Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47: 371–380PubMedCrossRefGoogle Scholar
  9. 9.
    Zhen Y, Lui MS, Weber G (1983) Effects of acivicin and dipyridamole on hepatoma 3924A cells. Cancer Res 43: 1616–1619PubMedGoogle Scholar
  10. 10.
    Chan TCK, Howell SB (1985) Mechanism of synergy between N-phosphoacetyl-L- aspartate and dipyridamole in a human ovarian carcinoma cell line. Cancer Res 45: 3598–3604PubMedGoogle Scholar
  11. 11.
    Kusumoto H, Maehara Y, Anai H, Kusumoto T, Sugimachi K (1988) Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo. Cancer Res 48: 1208–1212PubMedGoogle Scholar
  12. 12.
    Yang L, Rowe TC, Liu LF (1985) Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res 45: 5872–5876PubMedGoogle Scholar
  13. 13.
    Wang JC (1987) Recent studies of DNA topoisomerases. Biochem Biophys Acta 909: 1–9PubMedGoogle Scholar
  14. 14.
    Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365–15370PubMedGoogle Scholar
  15. 15.
    Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE (1986) Proliferation dependence of topoisomerase Il-mediated drug action. Biochemistry 25: 2248–2256PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1991

Authors and Affiliations

  • Takanori Ohnishi
  • Hiromitsu Iwasaki
  • Norio Arita
  • Shoju Hiraga
  • Toru Hayakawa
    • 1
  1. 1.Department of NeurosurgeryOsaka University Medical SchoolOsaka, 553Japan

Personalised recommendations